
Mucopolysaccharidosis Type I: Strategic Shift Underway as Gene Therapies &and Next-Gen ERTs Challenge Market Dominance
MPS I market evolution accelerates as gene therapies and BBB-penetrant ERTs emerge, challenging Sanofi’s Aldurazyme in a high-value orphan space. AUSTIN, TX, UNITED STATES, June 8, 2025 /EINPresswire.com/ -- The treatment landscape for …